| Literature DB >> 15734051 |
Merardo Pujol1, Nadia I Ramírez, Marta Ayala, Jorge V Gavilondo, Rodolfo Valdés, Meilyn Rodríguez, José Brito, Sigifredo Padilla, Leonardo Gómez, Biunaiky Reyes, Rudy Peral, Marlene Pérez, José L Marcelo, Lorely Milá, Rafael F Sánchez, Rolando Páez, José A Cremata, Gil Enríquez, Otto Mendoza, Mercedes Ortega, Carlos Borroto.
Abstract
The use of transgenic plants for the production of pharmaceutical compounds has received increasing attention in the last few years. However, many technological and regulatory issues regarding the practical exploitation of this alternative system of production remain to be solved; a situation that explains the lack of commercial products derived from such a system. This paper reports the expression in transgenic plants and cells of a single-chain antibody variable-region fragment (scFv) and a mouse monoclonal antibody to the hepatitis B virus surface antigen (HBsAg). The large-scale purification of the scFv from plants and its use for immunopurification of HBsAg are also described, together with elements concerning regulatory issues and technologies for compliance with good manufacturing and agricultural practices.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15734051 DOI： 10.1016/j.vaccine.2004.11.023
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641